For example, the hepatocyte-targeted N-acetylgalactosamine (GalNac)-conjugated ASO improves MASH and hepatic fibrosis in PNPLA3 rs738409 GG knock-in mice fed with a steatogenic diet; PNPLA3 silencing through short-hairpin RNA improves liver steatosis in PNPLA3 rs738409 GG knock-in mice fed a high fructose diet; the administration of lipid nanoparticles containing siRNA against human PNPLA3 improves histological features of MASH including liver fibrosis, shown in Figure 3 [114,115,116,117]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.